Drug Trial Radar · NCT04152499
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,410
Actual
Start
Feb 28, 2020
Primary completion
Nov 30, 2025
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Klus Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma 10. Cervical cancer
Conditions
- Epithelial Ovarian Cancer
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Urothelial Carcinoma
- Non-Small Cell Lung Cancer
- Small-Cell Lung Cancer
- Endometrial Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Breast Cancer
- Cervical Cancer
Interventions
SKB264Drug
SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Maximum Tolerated Dose (MTD) and Recommended Doses for Expansion (RDEs)Time frame: Assess up to 12 months
- Phase II: Objective Response Rate (ORR)Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Locations
109 sites in 6 countries. Site status is shown where the registry gives one.
Los Angeles Hematology Oncology Medical Group
Glendale, California
University of California Los Angeles
Los Angeles, California
Florida Cancer Specialists and Research Institute
Sarasota, Florida
START MidWest
Grand Rapids, Michigan
The University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Oklahoma Cancer Specialists and Research Institute, LLC
Tulsa, Oklahoma
Providence Cancer Institute, Franz Clinic
Portland, Oregon
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Sunnybrook Research Institute
Toronto, Ontario, Canada
MUHC,Glen - Women's Health Research Unit
Montreal, Quebec, Canada
Centro de Estudios Clínicos SAGA
Providencia, Chile
Centro de Investigacion Clinica Bradford Hill
Santiago, Chile
Pontificia Universidad Catolica de Chile - CICUC
Santiago, Chile
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China
Anhui Cancer Hospital
Hefei, Anhui, China
AnHui Provincial Cancer Hospital
Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The First Affiliated Hospital of USTC Anhui Provincial Hospital
Hefei, Anhui, China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Chinese PLA General Hospital (301 Hospital)
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Chongqing University Cancer Hosptital
Chongqing, Chongqing Municipality, China
900TH Hospital of Joint Logistics Support Force
Fuzhou, Fujian, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Fujian Medical University Uion Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital Of Xiamen University
Xiamen, Fujian, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Affiliated Hospital of Guangdong Medical University
Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Sun Yat-Sen Memorial Hospital , Sun Yat-sen University
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.